New progress on the diagnosis and management of chronic obstructive pulmonary disease_West China Medical Journal

Authors：

 CHEN Rongchang

Department of Respiratory and Critical Diseases, the First Affiliated Hospital of Guangzhou Medical University; Institute of Respiratory Health; State Key Laboratory for Respiratory Diseases; National Clinical Research Center for Respiratory Diseases; Guangzhou, Guangdong 510120, P. R. China;

Corresponding author：

CHEN Rongchang, Email: chenrc@vip.163.com

Keywords：

Chronic obstructive pulmonary disease; Phenotypes; Individualized management

DOI：

10.7507/1002-0179.201710037

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Chronic obstructive pulmonary disease (COPD) is one of the common chronic airway disorders, which accounts for the third to fourth cause of death worldwide. Recently, the focuses of researches are on the multi-factorial risks for development of COPD, mechanisms related to COPD development, early detection and early intervention of COPD, individualized use of long-term maintenance medications as well as phenotypes of acute exacerbation of COPD and their corresponding management. There are huge amount of COPD patients with variety of risk factors or different phenotypes in China, which makes it possible to establish a network for cohort study or real life registration study of COPD. The results will provide new information on the characteristics of COPD in China. Individualized treatment could be recommended according to the phenotypes or endotypes information. All these new findings or progresses could provide impetus for improvement of the ability of research and clinical management of COPD to the worldwide top level.

Citation： CHEN Rongchang. New progress on the diagnosis and management of chronic obstructive pulmonary disease. West China Medical Journal, 2018, 33(1): 15-18. doi: 10.7507/1002-0179.201710037 Copy

1.	Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med, 2007, 176(8): 753-760.
2.	Liu SM, Zhou YM, Wang XP, et al. Biomass fuels are the probable risk factor of chronic obstructive pulmonary disease in rural south china. Thorax, 2007, 62: 889-897.
3.	周玉民, 王辰, 姚婉贞, 等. 职业接触粉尘和烟雾对慢性阻塞性肺疾病及呼吸道症状的影响. 中国呼吸与危重监护杂志, 2009, 8(1): 6-11.
4.	Andersen ZJ, Hvidberg M, Jensen SS, et al. Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: a cohort study. Am J Respir Crit Care Med, 2011, 183(4): 455-461.
5.	Liu S, Zhou Y, Liu S, et al. Association between exposure to ambient particulate matter and chronic obstructive pulmonary disease: results from a cross-sectional study in China. Thorax, 2017, 72(9): 788-795.
6.	Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet, 2005, 365: 2225-2236.
7.	Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med, 2009, 361(27): 2599-2608.
8.	胡国平, 彭公永, 胡锦兴, 等. 肿瘤坏死因子 α-308 基因多态性与慢性阻塞性肺疾病易感性的荟萃分析. 中华结核和呼吸杂志, 2007, 30(8): 588-594.
9.	Pillai SG, Ge D, Zhu G, et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet, 2009, 5(3): e1000421.
10.	Qiao D, Lange C, Beaty TH, et al. Exome sequencing analysis in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2016, 193(12): 1353-1363.
11.	Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J, 2013, 42(3): 636-646.
12.	Duvoix A, Dickens J, Haq I, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax, 2013, 68(7): 670-676.
13.	Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J, 2014, 44(6): 1697-1700.
14.	钟南山. 早发现、早诊断和早干预应是我国慢性阻塞性肺疾病防治的主要研究方向. 中华结核和呼吸杂志, 2012, 35(4): 243-245.
15.	Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med, 2011, 365(13): 1184-1192.
16.	Zhou Y, Zhong N, Li XC, et al. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med, 2017, 377(10): 923-935.
17.	Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med, 2017, 195(5): 557-582.
18.	Miravitiles M, Soler-Cataluna JJ, Cahell M, et al. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J, 2013, 41(6): 1252-1256..
19.	张弘, 蔡柏蔷. 慢性阻塞性肺疾病急性加重临床研究进展. 中国呼吸与危重监护杂志, 2016, 15(2): 198-202.
20.	Brightling CE. Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc, 2013, 10(Suppl): S214-S219.
21.	Wedzicha JA Ers Co-Chair, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J, 2017, 49(3): pii: 1600791.

1. Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med, 2007, 176(8): 753-760.
2. Liu SM, Zhou YM, Wang XP, et al. Biomass fuels are the probable risk factor of chronic obstructive pulmonary disease in rural south china. Thorax, 2007, 62: 889-897.
3. 周玉民, 王辰, 姚婉贞, 等. 职业接触粉尘和烟雾对慢性阻塞性肺疾病及呼吸道症状的影响. 中国呼吸与危重监护杂志, 2009, 8(1): 6-11.
4. Andersen ZJ, Hvidberg M, Jensen SS, et al. Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: a cohort study. Am J Respir Crit Care Med, 2011, 183(4): 455-461.
5. Liu S, Zhou Y, Liu S, et al. Association between exposure to ambient particulate matter and chronic obstructive pulmonary disease: results from a cross-sectional study in China. Thorax, 2017, 72(9): 788-795.
6. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet, 2005, 365: 2225-2236.
7. Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med, 2009, 361(27): 2599-2608.
8. 胡国平, 彭公永, 胡锦兴, 等. 肿瘤坏死因子 α-308 基因多态性与慢性阻塞性肺疾病易感性的荟萃分析. 中华结核和呼吸杂志, 2007, 30(8): 588-594.
9. Pillai SG, Ge D, Zhu G, et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet, 2009, 5(3): e1000421.
10. Qiao D, Lange C, Beaty TH, et al. Exome sequencing analysis in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2016, 193(12): 1353-1363.
11. Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J, 2013, 42(3): 636-646.
12. Duvoix A, Dickens J, Haq I, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax, 2013, 68(7): 670-676.
13. Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J, 2014, 44(6): 1697-1700.
14. 钟南山. 早发现、早诊断和早干预应是我国慢性阻塞性肺疾病防治的主要研究方向. 中华结核和呼吸杂志, 2012, 35(4): 243-245.
15. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med, 2011, 365(13): 1184-1192.
16. Zhou Y, Zhong N, Li XC, et al. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med, 2017, 377(10): 923-935.
17. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med, 2017, 195(5): 557-582.
18. Miravitiles M, Soler-Cataluna JJ, Cahell M, et al. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur Respir J, 2013, 41(6): 1252-1256..
19. 张弘, 蔡柏蔷. 慢性阻塞性肺疾病急性加重临床研究进展. 中国呼吸与危重监护杂志, 2016, 15(2): 198-202.
20. Brightling CE. Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc, 2013, 10(Suppl): S214-S219.
21. Wedzicha JA Ers Co-Chair, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J, 2017, 49(3): pii: 1600791.

Previous Article
合并侵袭性肺部真菌感染的支气管中央性肉芽肿病一例
Next Article
Hot topics on the diagnosis and antimicrobial therapy of ventilator-associated pneumonia

West China Medical Journal

New progress on the diagnosis and management of chronic obstructive pulmonary disease

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content